As part of our ongoing aim to bring you reports of interesting new studies, we have added a review of a recent study on Durvalumab for locally advanced, unresectable non-small cell lung cancer: PACIFIC study update.
Independent expert commentary is provided by Dr Thomas John, a medical oncologist and translational researcher at Austin Health and the Ludwig Institute for Cancer Research.
Please login below to download this issue (PDF)